TikTok blamed for the semaglutide shortage
A sudden rush on off-label scripts for the diabetes drug coincides with spruiking by ‘influencers’
GPs are being urged not to prescribe semaglutide (Ozempic) off label for obesity management as surging demand has created a shortage of the drug for people with type 2 diabetes.
Semaglutide manufacturer Novo Nordisk has informed the TGA that both strengths of the Ozempic pre-filled pen are in short supply as a result of an unexpected increase in patient demand.
Some commentators have linked the sudden intense interest in semaglutide to social media ‘influencers’ on TikTok spruiking its weight loss
